Press Releases NKGen Biotech, Inc.

Equities

NKGN

US65488A1016

End-of-day quote Nasdaq Other stock markets 18:00:00 2024-05-27 EDT			5-day change	1st Jan Change
1.5 ^USD	+5.63%		-19.35%	-45.45%

05-23	NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting	CI
05-20	NKGen Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL	05-24	AQ
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	05-23	AQ
NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease	05-20	AQ
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition	05-16	AQ
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease	04-29	AQ
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit	04-25	AQ
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology Annual Meeting	04-25	AQ
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	04-24	AQ
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's and Parkinson's Drug Development Summit	04-19	AQ
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit	04-18	AQ
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs	04-11	AQ
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's disease at the Tau2024 Global Conference	03-26	AQ
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference	03-25	AQ
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference	03-04	AQ
Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies	02-07	AQ
NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial	12-29	AQ
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease	12-28	AQ
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease	12-28	AQ
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease	12-27	AQ
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights	11-14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases NKGen Biotech, Inc.

Equities

NKGN

US65488A1016

Press Releases

Filters